Published in Proc Natl Acad Sci U S A on April 18, 2005
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin. Proc Natl Acad Sci U S A (2006) 2.10
New wirings in the survivin networks. Oncogene (2008) 1.76
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene (2008) 1.57
MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res (2011) 1.57
Nonreceptor tyrosine kinases in prostate cancer. Neoplasia (2007) 1.50
STAT3 mRNA and protein expression in colorectal cancer: effects on STAT3-inducible targets linked to cell survival and proliferation. J Clin Pathol (2007) 1.46
Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol (2009) 1.40
Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 1.33
JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther (2011) 1.29
Role of STAT3 in cancer metastasis and translational advances. Biomed Res Int (2013) 1.29
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.25
Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Mol Carcinog (2010) 1.12
LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model. Br J Cancer (2009) 1.10
Transcriptional and post-transcriptional controls of survivin in cancer cells: novel approaches for cancer treatment. J Exp Clin Cancer Res (2006) 1.09
Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol (2012) 1.02
6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res (2011) 1.02
Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer (2010) 1.00
Inhibition of Toxoplasma gondii by indirubin and tryptanthrin analogs. Antimicrob Agents Chemother (2008) 0.99
Cross-talk between phospho-STAT3 and PLCγ1 plays a critical role in colorectal tumorigenesis. Mol Cancer Res (2011) 0.98
ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol (2009) 0.97
Dietary ligands of the aryl hydrocarbon receptor induce anti-inflammatory and immunoregulatory effects on murine dendritic cells. Toxicol Sci (2011) 0.95
Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model. Cancer Microenviron (2010) 0.95
Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer. PLoS One (2014) 0.95
Dependence of Golgi apparatus integrity on nitric oxide in vascular cells: implications in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol (2011) 0.93
Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol (2011) 0.93
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) (2014) 0.91
Bioactivity of the Murex Homeopathic Remedy and of Extracts from an Australian Muricid Mollusc against Human Cancer Cells. Evid Based Complement Alternat Med (2010) 0.91
Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging. Am J Physiol Lung Cell Mol Physiol (2009) 0.90
Indirubin-3-monoxime exhibits anti-inflammatory properties by down-regulating NF-κB and JNK signaling pathways in lipopolysaccharide-treated RAW264.7 cells. Inflamm Res (2011) 0.90
Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol Oncol (2012) 0.90
Modulating polo-like kinase 1 as a means for cancer chemoprevention. Pharm Res (2010) 0.87
Traumatically injured astrocytes release a proteomic signature modulated by STAT3-dependent cell survival. Glia (2015) 0.87
Mutagenic Activity of Indigofera truxillensis and I. suffruticosa Aerial Parts. Evid Based Complement Alternat Med (2011) 0.87
Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol Oncol (2012) 0.86
12/15-lipoxygenase contributes to platelet-derived growth factor-induced activation of signal transducer and activator of transcription 3. J Biol Chem (2013) 0.85
Antimicrobial, antimycobacterial and antibiofilm properties of Couroupita guianensis Aubl. fruit extract. BMC Complement Altern Med (2012) 0.83
New small-molecule inhibitors effectively blocking picornavirus replication. J Virol (2014) 0.82
Indirubin-3'-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc Res (2013) 0.81
Indirubin derivative E804 inhibits angiogenesis. BMC Cancer (2012) 0.81
Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases. Evid Based Complement Alternat Med (2015) 0.80
Delivery of the co-expression plasmid pEndo-Si-Stat3 by attenuated Salmonella serovar typhimurium for prostate cancer treatment. J Cancer Res Clin Oncol (2013) 0.79
Are the Traditional Medical Uses of Muricidae Molluscs Substantiated by Their Pharmacological Properties and Bioactive Compounds? Mar Drugs (2015) 0.79
Indirubin-3'-(2,3 dihydroxypropyl)-oximether (E804) is a potent modulator of LPS-stimulated macrophage functions. Toxicol Appl Pharmacol (2012) 0.79
Combined Effects of Muricid Extract and 5-Fluorouracil on Intestinal Toxicity in Rats. Evid Based Complement Alternat Med (2015) 0.78
RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification. Oncotarget (2015) 0.78
Integration of Chinese Herbal Medicine Therapy Improves Survival of Patients With Chronic Lymphocytic Leukemia: A Nationwide Population-Based Cohort Study. Medicine (Baltimore) (2016) 0.78
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. Drug Des Devel Ther (2009) 0.78
An indirubin derivative, indirubin-3'-monoxime suppresses oral cancer tumorigenesis through the downregulation of survivin. PLoS One (2013) 0.76
Spirooxindole derivative SOID-8 induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. PLoS One (2012) 0.76
Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One (2013) 0.76
Anti-inflammatory effects of indirubin derivatives on influenza A virus-infected human pulmonary microvascular endothelial cells. Sci Rep (2016) 0.76
Characterization of anti-leukemia components from Indigo naturalis using comprehensive two-dimensional K562/cell membrane chromatography and in silico target identification. Sci Rep (2016) 0.76
VIP inhibits human HepG2 cell proliferation in vitro. Regul Pept (2007) 0.75
Schiff bases of indoline-2,3-dione (isatin) with potential antiproliferative activity. Chem Cent J (2012) 0.75
Indirubin Increases CD4+CD25+Foxp3+ Regulatory T Cells to Prevent Immune Thrombocytopenia in Mice. PLoS One (2015) 0.75
Enhancing effects of indirubin on the arsenic disulfide-induced apoptosis of human diffuse large B-cell lymphoma cells. Oncol Lett (2015) 0.75
Rapid Identification and Verification of Indirubin-Containing Medicinal Plants. Evid Based Complement Alternat Med (2015) 0.75
Isatin derivatives with activity against apoptosis-resistant cancer cells. Bioorg Med Chem Lett (2016) 0.75
Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation. J Exp Clin Cancer Res (2017) 0.75
6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti-androgen Receptor Therapy in Prostate Cancer Cells. Mol Ther (2017) 0.75
Stat3 as an oncogene. Cell (1999) 17.39
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
STATs in oncogenesis. Oncogene (2000) 8.60
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 7.15
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem (1997) 6.99
The role of STATs in transcriptional control and their impact on cellular function. Oncogene (2000) 6.42
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 6.28
A renaissance for SRC. Nat Rev Cancer (2004) 6.27
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Src family kinases, key regulators of signal transduction. Oncogene (2004) 4.30
Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 4.22
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 3.96
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest (2001) 3.79
STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 3.75
Role of Src expression and activation in human cancer. Oncogene (2000) 3.41
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 2.81
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem (2001) 2.79
Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol (1999) 2.78
Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem (2001) 2.58
STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets (2004) 2.21
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov Today (2004) 1.64
Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem (2000) 1.61
ATP-site directed inhibitors of cyclin-dependent kinases. Curr Med Chem (1999) 1.52
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res (1999) 1.51
Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma (2002) 1.33
Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway. J Biol Chem (1998) 1.27
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer (2001) 1.24
Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem (1997) 1.23
Roscovitine inhibits STAT5 activity and induces apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer Res (2003) 1.04
Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure (2001) 1.00
A mitotic function for Src? Trends Cell Biol (1994) 0.99
Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis. Cancer Epidemiol Biomarkers Prev (2001) 0.97
Activation of the Src family of tyrosine kinases in mammary tumorigenesis. Adv Cancer Res (1994) 0.93
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
The STATs of cancer--new molecular targets come of age. Nat Rev Cancer (2004) 13.07
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol (2007) 8.29
MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med (2005) 6.58
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res (2002) 5.84
Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A (2007) 4.77
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol (2008) 4.45
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25
Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol (2004) 3.24
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Retracted Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem (2002) 2.97
Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol (2005) 2.96
Retracted Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem (2003) 2.89
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene (2002) 2.81
Stat3 regulates genes common to both wound healing and cancer. Oncogene (2005) 2.80
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs (2009) 2.58
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene (2003) 2.54
STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res (2008) 2.46
Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res (2003) 2.43
A critical role for Stat3 signaling in immune tolerance. Immunity (2003) 2.41
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med (2010) 2.41
Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res (2006) 2.41
microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood (2010) 2.37
Retracted MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem (2010) 2.34
Stat3 controls lysosomal-mediated cell death in vivo. Nat Cell Biol (2011) 2.28
Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst (2008) 2.20
Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem (2004) 2.11
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res (2006) 2.11
Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther (2004) 2.10
Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem (2008) 1.98
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A (2006) 1.96
Expression and role of Foxa proteins in prostate cancer. Prostate (2006) 1.96
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res (2007) 1.96
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A (2012) 1.94
Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev (2005) 1.93
Role of Stat3 in regulating p53 expression and function. Mol Cell Biol (2005) 1.91
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol (2007) 1.79
AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci (2005) 1.72
Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther (2004) 1.70
Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene (2005) 1.70
A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem (2005) 1.70
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther (2006) 1.69
Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor. J Biol Chem (2003) 1.68
miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology (2010) 1.66
Akt and CHIP coregulate tau degradation through coordinated interactions. Proc Natl Acad Sci U S A (2008) 1.66
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. Clin Cancer Res (2010) 1.64
LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res (2011) 1.64
Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer (2006) 1.64
Retracted Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem (2003) 1.63
p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res (2003) 1.62
Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res (2010) 1.60
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther (2008) 1.56
A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol (2010) 1.56
Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res (2009) 1.55
Prediction of radiation sensitivity using a gene expression classifier. Cancer Res (2005) 1.53
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res (2008) 1.52
Retracted AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem (2003) 1.49
Retracted IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem (2011) 1.47
Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene (2002) 1.47
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther (2007) 1.45
Cytoplasmic transport of Stat3 by receptor-mediated endocytosis. EMBO J (2002) 1.43
Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res (2008) 1.43
The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? Cancer Res (2008) 1.43